Objectives The treatment for COVID-19 often utilizes immune-modulating drugs. These
drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a …

Objectives To better understand the factors that influence the humoral immune response to
vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases …

Background & Aims Patients with immune-mediated inflammatory diseases (IMIDs) have an
increased risk of coronavirus disease 2019 (COVID-19), primarily attributed to the use of …

BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …

At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

Objectives Successful vaccination is key to overcoming the COVID-19 pandemic.
Immunosuppressive medication is known to potentially compromise vaccination responses …

Objective Immunogenicity and safety following receipt of the standard SARS–CoV‐2
vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are …

Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly
treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

Abstract Coronavirus disease 2019 (COVID-19) pandemic has become challenging even for
the most durable healthcare systems. It seems that vaccination, one of the most effective …